Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Trial Evaluating the Combination of TG4001 and Avelumab in Patients With HPV-16 Positive Recurrent or Metastatic Malignancies.

NCT03260023 is registered in ClinicalTrials.gov with Transgene as lead sponsor.

NCT NCT03260023
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03260023 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Trial Evaluating the Combination of TG4001 and Avelumab in Patients With HPV-16 Positive Recurrent or Metastatic Malignancies.
Lead sponsor
Transgene
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 1, 2017
Completion date
December 31, 2026
Enrollment
143 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

hpv-related anal squamous cell carcinoma, hpv-related carcinoma, hpv-related cervical carcinoma, hpv-related penile squamous cell carcinoma, hpv-related vulvar squamous cell carcinoma